Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
Information source: Kessler Foundation
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Aphasia; Stroke
Intervention: Levetiracetam (Drug); Levetiracetam (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: Kessler Foundation Official(s) and/or principal investigator(s): A.M. Barrett, MD, Principal Investigator, Affiliation: Kessler Foundation
Summary
The study investigates the possibility that levetiracetam may improve the symptoms of
chronic post-stroke aphasia.
Clinical Details
Official title: Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Speech and language assessment
Secondary outcome: Memory assessment
Detailed description:
In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will
evaluate their speech, language, and memory in an ABAB design.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stroke
- Aphasia
- Can give consent
Exclusion Criteria:
- Renal failure
- Pregnancy
- Other neurological condition
Locations and Contacts
Kessler Foundation, West Orange, New Jersey 07052, United States
Additional Information
Starting date: September 2005
Last updated: March 31, 2015
|